A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Status:
Active, not recruiting
Trial end date:
2023-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered
orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin
and evidence of ongoing hemolysis that requires treatment intervention.